Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy
- PMID: 15191618
- PMCID: PMC446197
- DOI: 10.1186/1471-2377-4-8
Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy
Abstract
Background: What currently appears to be irreversible axonal loss in normal appearing white matter, measured by proton magnetic resonance spectroscopy is of great interest in the study of Multiple Sclerosis. Our aim is to determine the axonal damage in normal appearing white matter measured by magnetic resonance spectroscopy and to correlate this with the functional disability measured by Multiple Sclerosis Functional Composite scale, Neurological Rating Scale, Ambulation Index scale, and Expanded Disability Scale Score.
Methods: Thirty one patients (9 male and 22 female) with relapsing remitting Multiple Sclerosis and a Kurtzke Expanded Disability Scale Score of 0-5.5 were recruited from four hospitals in Andalusia, Spain and included in the study. Magnetic resonance spectroscopy scans and neurological disability assessments were performed the same day.
Results: A statistically significant correlation was found (r = -0.38 p < 0.05) between disability (measured by Expanded Disability Scale Score) and N-Acetyl Aspartate (NAA/Cr ratio) levels in normal appearing white matter in these patients. No correlation was found between the NAA/Cr ratio and disability measured by any of the other disability assessment scales.
Conclusions: There is correlation between disability (measured by Expanded Disability Scale Score) and the NAA/Cr ratio in normal appearing white matter. The lack of correlation between the NAA/Cr ratio and the Multiple Sclerosis Functional Composite score indicates that the Multiple Sclerosis Functional Composite is not able to measure irreversible disability and would be more useful as a marker in stages where axonal damage is not a predominant factor.
Figures
Similar articles
-
Imaging axonal damage of normal-appearing white matter in multiple sclerosis.Brain. 1998 Jan;121 ( Pt 1):103-13. doi: 10.1093/brain/121.1.103. Brain. 1998. PMID: 9549491
-
The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography.Eur J Neurol. 2016 Dec;23(12):1769-1774. doi: 10.1111/ene.13116. Epub 2016 Sep 3. Eur J Neurol. 2016. PMID: 27591406
-
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis.Neurology. 2007 Jul 3;69(1):63-7. doi: 10.1212/01.wnl.0000265054.08610.12. Neurology. 2007. PMID: 17606882
-
Imaging axonal damage in multiple sclerosis by means of MR spectroscopy.Neurol Sci. 2000;21(4 Suppl 2):S883-7. doi: 10.1007/s100720070031. Neurol Sci. 2000. PMID: 11205368 Review.
-
The contribution of (1)H-magnetic resonance spectroscopy in defining the pathophysiology of multiple sclerosis.Ital J Neurol Sci. 1999;20(5 Suppl):S241-5. doi: 10.1007/s100729970004. Ital J Neurol Sci. 1999. PMID: 10662956 Review.
Cited by
-
Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis.AJNR Am J Neuroradiol. 2010 Jan;31(1):180-4. doi: 10.3174/ajnr.A1738. Epub 2009 Sep 3. AJNR Am J Neuroradiol. 2010. PMID: 19729541 Free PMC article.
-
Current Methods of Magnetic Resonance for Noninvasive Assessment of Molecular Aspects of Pathoetiology in Multiple Sclerosis.Int J Mol Sci. 2020 Aug 25;21(17):6117. doi: 10.3390/ijms21176117. Int J Mol Sci. 2020. PMID: 32854318 Free PMC article. Review.
-
Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?Acta Neuropathol Commun. 2014 Aug 27;2:97. doi: 10.1186/s40478-014-0097-7. Acta Neuropathol Commun. 2014. PMID: 25159125 Free PMC article. Review.
-
Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine and marijuana.Behav Brain Res. 2013 Jun 1;246:154-61. doi: 10.1016/j.bbr.2013.02.028. Epub 2013 Mar 4. Behav Brain Res. 2013. PMID: 23466689 Free PMC article.
-
Neuroprotection in multiple sclerosis: a therapeutic approach.CNS Drugs. 2013 Oct;27(10):799-815. doi: 10.1007/s40263-013-0093-7. CNS Drugs. 2013. PMID: 23955320 Review.
References
-
- Charcot M. Histologie de la sclerose en plaques. Gaz Hosp. 1868;141:554–8.
-
- McDonald WI. Rachelle Fishman – Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol. 1994;53:338–343. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources